HNWAG
SRPT icon

High Net Worth Advisory Group’s Sarepta Therapeutics SRPT Stock Holding History

High Net Worth Advisory Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$78K – 718
2022
Q1 		$78K Hold
1,000
– – 0.03% 278
2021
Q4 		$90K Buy
+1,000
New +$85.5K 0.03% 272

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

High Net Worth Advisory Group's SRPT Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 1,000 shares — an estimated $78K sold.

High Net Worth Advisory Group first reported a position in SRPT in Q4 2021 and held it in 2 quarters. The position peaked at $90K in Q4 2021. 332 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Sarepta Therapeutics shares in Q2 2022, an estimated $78K.
  • High Net Worth Advisory Group first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 2 quarters.
  • High Net Worth Advisory Group's Sarepta Therapeutics position peaked at $90K in Q4 2021.
  • 332 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.